Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context (Q37288832)

19 August 2017

Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context (English)

1 reference

19 August 2017

Eric Feuer

1 reference

19 August 2017

Angela Mariotto

1 reference

19 August 2017

Gerrit Draisma

1 reference

19 August 2017

Ruth Etzioni

1 reference

19 August 2017

Alex Tsodikov

1 reference

19 August 2017

Elisabeth Wever

1 reference

19 August 2017

Roman Gulati

1 reference

19 August 2017

Harry de Koning

1 reference

19 August 2017

language of work or name

English

0 references

publication date

10 March 2009

1 reference

Journal of the National Cancer Institute

19 August 2017

1 reference

19 August 2017

101

1 reference

19 August 2017

1 reference

19 August 2017

374-383

1 reference

Modeling Disease Progression with Longitudinal Markers

19 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720697

What is low-risk prostate cancer and what is its natural history?

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720697

The influence of finasteride on the development of prostate cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720697

Screening for prostate cancer: estimating the magnitude of overdetection

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720697

Serum concentrations of prostate specific antigen and its complex with alpha 1-antichymotrypsin before diagnosis of prostate cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720697

Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial of the National Cancer Institute

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720697

Estimation of the duration of a pre-clinical disease state using screening data

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720697

Pathological characteristics of prostate cancer detected through prostate specific antigen based screening

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720697

Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720697

Lead time associated with screening for prostate cancer.

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720697

International trends in prostate-cancer mortality in the "PSA ERA".

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720697

Prostate-specific antigen as predictor of prostate cancer in black men and white men.

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720697

Nonparametric Estimation of the Size-Metastasis Relationship in Solid Cancers

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720697

Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends

26 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720697

Reconstructing PSA testing patterns between black and white men in the US from Medicare claims and the National Health Interview Survey

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720697

Five-year follow-up of health-related quality of life after primary treatment of localized prostate cancer.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720697

Combining longitudinal studies of PSA.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720697

MISCAN: estimating lead-time and over-detection by simulation

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720697

Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer.

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720697

Modeling cancer detection: tumor size as a source of information on unobservable stages of carcinogenesis

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720697

Cancer surveillance series: interpreting trends in prostate cancer--part III: Quantifying the link between population prostate-specific antigen testing and recent declines in prostate cancer mortality

3 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2720697

Longitudinal analysis of serial measurements of free and total PSA among men with and without prostatic cancer

3 September 2018

1 reference

12 December 2020

Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer

1 reference

12 December 2020

A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer

1 reference

12 December 2020

Overdiagnosis Due to Prostate-Specific Antigen Screening: Lessons From U.S. Prostate Cancer Incidence Trends

1 reference

12 December 2020

Would prostate cancer detected by screening with prostate-specific antigen develop into clinical cancer if left undiagnosed? A comparison of two population-based studies in Sweden

1 reference

12 December 2020

Simplified models of screening for chronic disease: estimation procedures from mass screening programmes

1 reference

12 December 2020

A population model of prostate cancer incidence

1 reference

12 December 2020

How much of the recent rise in breast cancer incidence can be explained by increases in mammography utilization? A dynamic population model approach

1 reference

12 December 2020

Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer

1 reference

12 December 2020

Prostate cancer mortality reduction by screening: Power and time frame with complete enrollment in the European randomised screening for prostate cancer (ERSPC) trial

1 reference

12 December 2020

Lead-time in prostate cancer screening (Finland)

1 reference

12 December 2020

Gleason score, age and screening: Modeling dedifferentiation in prostate cancer

1 reference

12 December 2020

Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach

1 reference

12 December 2020

Identifiers

DOI

10.1093/JNCI/DJP001

1 reference

19 August 2017

1 reference

19 August 2017

PubMed publication ID

19276453

1 reference